Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib
Apatinib was the first anti-angiogenic agent approved for treatment of metastatic gastric cancer (GC). However, the emergence of resistance was inevitable. Thus investigating new and valuable off-target effect...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Bei Zhang, Yan Chen, Xinqi Chen, Zhiyao Ren, Hong Xiang, Lipeng Mao and Guodong Zhu Tags: Research Source Type: research